Targeting epidermal growth factor receptor in lung cancer

摘要: Among the most promising agents in clinical development to treat non-small-cell lung cancer (NSCLC) are epidermal growth factor receptor (EGFR) targeting agents. A series of recent studies have demonstrated activity anti-EGFR targeted therapies for NSCLC. In advanced NSCLC that is refractory chemotherapy, antitumor responses been reported with EGFR tyrosine kinase inhibitors (ZD1839 and OSI-774). The role ZD1839 OSI-774 as possible additions standard chemotherapy first-line setting has also evaluated, conducted date should respond question whether these compounds could provide a survival benefit. Other areas research involve looking at neoadjuvant treatment stage III planning chemoprevention studies. These exciting results plans further complemented by an emerging number development, including both monoclonal antibodies (ie, IMC-C225) other inhibitors, directed EGFR.